{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T05:05:08Z","timestamp":1755925508446},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,8,15]],"date-time":"2009-08-15T00:00:00Z","timestamp":1250294400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:p>Cyclooxygenase\u20102 (COX\u20102) has been found to be associated with the development and progression of various cancers. Our previous study showed a high expression rate of COX\u20102 in paraffin\u2010embedded tissue specimens from patients with vulvar cancer. In this study, we evaluated the efficacy of celecoxib, a selective COX\u20102 inhibitor, as a chemosensitizing agent with cisplatin in vulvar cancer cells A431 and SW962. COX\u20102 was expressed in both A431 and SW962 vulvar cancer cell lines. COX\u20101 was expressed in A431 but not in SW962. MTT [3\u2010(4,5\u2010dimethylthiazol\u20102\u2010yl)\u20102,5\u2010diphenyltetrazoliumbromide] assay showed that treatment with 30 \u03bcmol\/L celecoxib had no effect on cell growth in A431 cells for 72 h. However, combined treatment with celecoxib and cisplatin induced a significant reduction in cell growth compared to single treatment with cisplatin. Interestingly, single treatment with celecoxib or cisplatin and combined treatment of 10 \u03bcmol\/L celecoxib with 10 \u03bcmol\/L cisplatin increased COX\u20102 expression. However, the combination of 30 \u03bcmol\/L celecoxib and 30 \u03bcmol\/L cisplatin reduced COX\u20102 expression to the control state. Inhibition of cell growth by celecoxib alone and in combination with cisplatin was independent of the expression level of COX\u20102 induced by these agents. While treatment with 10 \u03bcmol\/L celecoxib or 10 \u03bcmol\/L piroxicam significantly suppressed the activity of COX enzymes, neither agent affected the growth of A431 and SW962 cells at this concentration. Taken together, celecoxib could be used as a chemosensitizing agent in vulva cancer cells; the anticancer activity of celecoxib seemed to be independent of COX.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2009.04888.x","type":"journal-article","created":{"date-parts":[[2009,8,15]],"date-time":"2009-08-15T04:21:44Z","timestamp":1250310104000},"page":"635-641","source":"Crossref","is-referenced-by-count":17,"title":["Celecoxib Potentiates the Anticancer Effect of Cisplatin on Vulvar Cancer Cells Independently of Cyclooxygenase"],"prefix":"10.1111","volume":"1171","author":[{"given":"Su\u2010Hyeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su\u2010Hyeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo\u2010Choel","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong\u2010Sang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,8,15]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"295","article-title":"Steroids, aspirin, and inflammation","volume":"2","author":"Kalter E.","year":"1997","journal-title":"Inflammation"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.38.1.97"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203286"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.10068"},{"key":"e_1_2_7_6_2","first-page":"18","article-title":"Epidemiology of NSAID induced gastrointestinal complications","volume":"56","author":"Singh G.","year":"1999","journal-title":"J. Rheumatol. Suppl."},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906173402407"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.08.051"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.065003"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80121-1"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/107327480200902S04"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20878"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2005.05.028"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21325"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1397.018"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-004-0567-6"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.09.005"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.8.585"},{"key":"e_1_2_7_19_2","first-page":"2029","article-title":"Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX\u20102\u2010negative hematopoietic and epithelial cell lines","volume":"62","author":"Waskewich C.","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2005.05.028"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-5-19"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.3171\/foc.2006.20.4.14"},{"key":"e_1_2_7_23_2","article-title":"Celecoxib, a cyclooxygenase\u20102 inhibitor, induces apoptosis in human osteosarcoma cell line MG\u201063 via down\u2010regulation of PI3K\/Akt","author":"Liu B.","year":"2007","journal-title":"Cell Biol. Int."},{"key":"e_1_2_7_24_2","first-page":"665","article-title":"Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase\u20102 inhibitor, in human head and neck carcinoma cell lines","volume":"23","author":"Hashitani S.","year":"2003","journal-title":"Int. J. Oncol."},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M203218200"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2009.04888.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2009.04888.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T03:40:12Z","timestamp":1695699612000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2009.04888.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1749-6632.2009.04888.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2009.04888.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}